Biofrontera vs Cumberland Pharmaceuticals
Biofrontera and Cumberland Pharmaceuticals are similar in size: $41.7m and $44.5m of revenue in their latest fiscal years. Cumberland Pharmaceuticals grew faster (17.6% against 11.7%). Cumberland Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -6.4% against -25.3%.
| Latest fiscal year | BiofronteraBFRI, 2025 | Cumberland PharmaceuticalsCPIX, 2025 |
|---|---|---|
| Revenue | $41.7m | $44.5m |
| Revenue growth | 11.7% | 17.6% |
| Net income | −$10.5m | −$2.8m |
| Operating margin | — | -6.3% |
| Net margin | -25.3% | -6.4% |
| Return on equity | -141.3% | -11.9% |
| Free cash flow | −$13.4m | $4.8m |
| Cash | $6.4m | $11.4m |
| Total debt | $0 | $5.2m |
| Debt to equity | — | 21.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $263,478 |
| Employees | 92 | 93 |
| Market value | $12.5m | $64.4m |
| Price vs our value range | — | Above our value range |
| Moat score | — | 57 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |